A technical overview of what mRNA synthesis looks like in a research-lab or well-resourced DIY setting. What the workflow requires, what can go wrong, and why this is not a casual undertaking.
In Vitro Transcription — uses T7 RNA polymerase + NTPs + a DNA template. Commercial kits (e.g., NEB HiScribe) produce mg quantities of mRNA in a tube reaction over hours.
mRNA stability requires a 5' cap. Done via cap analog (ARCA) during IVT, or by post-transcriptional capping with vaccinia capping enzyme. Cap-0 vs Cap-1 matters for immunogenicity.
Remove unincorporated NTPs, template DNA, and contaminating dsRNA. Standard: LiCl precipitation, then silica column, then sometimes HPLC. dsRNA is a major immunogenicity driver — hard to fully remove.
mRNA alone degrades in blood. Lipid nanoparticles (LNP) protect and deliver. Requires microfluidic mixing, specific ionizable lipids (SM-102, ALC-0315), PEG-lipid, cholesterol, and DSPC. Formulation is where most DIY attempts fail.
Producing mRNA as a research compound in the US is legal in a research-lab context. Injecting DIY-produced mRNA into humans is not legal — it falls under FDA drug regulation. DIYbio communities have explored this academically.
LNP formulation. IVT synthesis is kit-based and reproducible; capping is solved by modern protocols; purification is work but feasible. LNPs require microfluidic mixing, specific lipid chemistry, and quality control that's hard to replicate in small-lab settings.
Practically — no, not in a way that produces safe injectable product. The capital, expertise, and QC required are substantial. The workflow exists in research labs and specialized contract manufacturers for a reason.
mRNA and peptide therapeutics are related technologies — both are biologic modalities with overlapping production principles. Understanding mRNA production helps contextualize how peptide therapeutics are made and why vendor quality varies.
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
This page is educational. It describes the technical workflow of mRNA production as covered in open literature. It is not a how-to for producing therapeutics for human use.
Producing injectable biologics outside of regulated infrastructure is illegal in most jurisdictions and carries real health risks. Not medical or technical advice.